Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Liver Diseases

Free Subscription 08.04.2019 2 Am J Pathol 6 Biochem Biophys Res Commun 2 BMC Cancer 1 BMC Gastroenterol 1 Dig Dis Sci 5 Eur Radiol 4 Gastroenterology 6 Hepatology 1 Int J Cancer 2 J Comput Assist Tomogr 1 J Gastroenterol 3 J Gastroenterol Hepatol 3 J Hepatol 2 Lancet Oncol 1 Oncogene 6 PLoS One 3 Transplantation

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Pathol

1. GUNTHER S, Perros F, Rautou PE, Girerd B, et al
   Understanding Hepatic and Pulmonary Veno-Occlusive Disease: Similarities and Differences.
   Am J Pathol. 2019 Mar 26. pii: S0002-9440(18)30320.
   PubMed     Text format     Abstract available
   
   
2. WILKINSON PD, Alencastro F, Delgado ER, Leek MP, et al
   Polyploid Hepatocytes Facilitate Adaptation and Regeneration to Chronic Liver Injury.
   Am J Pathol. 2019 Mar 27. pii: S0002-9440(18)30970.
   PubMed     Text format     Abstract available
   
   

   
   Biochem Biophys Res Commun

3. QIAO Y, Zhang X, Zhao G, Liu Z, et al
   Hepatocellular iNOS protects liver from ischemia/reperfusion injury through HSF1-dependent activation of HSP70.
   Biochem Biophys Res Commun. 2019 Mar 28. pii: S0006-291X(19)30527.
   PubMed     Text format     Abstract available
   
   
4. WU LW, Zhou DM, Zhang ZY, Zhang JK, et al
   Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
   Biochem Biophys Res Commun. 2019 Mar 28. pii: S0006-291X(19)30554.
   PubMed     Text format     Abstract available
   
   
5. LI YL, Li XQ, Wang YD, Shen C, et al
   Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo.
   Biochem Biophys Res Commun. 2019 Mar 29. pii: S0006-291X(19)30460.
   PubMed     Text format     Abstract available
   
   
6. YANG S, Wei L, Xia R, Liu L, et al
   Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPARalpha.
   Biochem Biophys Res Commun. 2019 Mar 27. pii: S0006-291X(19)30525.
   PubMed     Text format     Abstract available
   
   
7. HOSHI T, Watanabe Miyano S, Watanabe H, Sonobe RMK, et al
   Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
   Biochem Biophys Res Commun. 2019 Feb 16. pii: S0006-291X(19)30196.
   PubMed     Text format     Abstract available
   
   
8. CHOI S, Jung HJ, Kim MW, Kang JH, et al
   A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice.
   Biochem Biophys Res Commun. 2019 Mar 29. pii: S0006-291X(19)30556.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. ZANELLI M, Mengoli MC, Del Sordo R, Cagini A, et al
   Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma.
   BMC Cancer. 2018;18:1115.
   PubMed     Text format     Abstract available
   
   
10. OH CR, Kong SY, Im HS, Kim HJ, et al
    Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    BMC Cancer. 2019;19:292.
    PubMed     Text format     Abstract available
    
    

    
    BMC Gastroenterol

11. FOUSEKIS FS, Katsanos KH, Theopistos VI, Baltayiannis G, et al
    Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study.
    BMC Gastroenterol. 2019;19:48.
    PubMed     Text format     Abstract available
    
    

    
    Dig Dis Sci

12. YU B, Ding Y, Liao X, Wang C, et al
    Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
    Dig Dis Sci. 2019 Apr 4. pii: 10.1007/s10620-019-05608.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

13. REIZINE E, Ronot M, Pigneur F, Purcell Y, et al
    Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
    Eur Radiol. 2019 Apr 1. pii: 10.1007/s00330-019-06150.
    PubMed     Text format     Abstract available
    
    
14. CHEUNG HMC, Karanicolas PJ, Coburn N, Seth V, et al
    Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases.
    Eur Radiol. 2019;29:1032-1038.
    PubMed     Text format     Abstract available
    
    
15. KIM YY, Choi JY, Sirlin CB, An C, et al
    Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).
    Eur Radiol. 2019;29:1124-1132.
    PubMed     Text format     Abstract available
    
    
16. IEZZI R, Pompili M, Rinninella E, Annicchiarico E, et al
    TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
    Eur Radiol. 2019;29:1285-1292.
    PubMed     Text format     Abstract available
    
    
17. JOSKOWICZ L, Cohen D, Caplan N, Sosna J, et al
    Inter-observer variability of manual contour delineation of structures in CT.
    Eur Radiol. 2019;29:1391-1399.
    PubMed     Text format     Abstract available
    
    

    
    Gastroenterology

18. ELSSNER C, Goeppert B, Longerich T, Scherr AL, et al
    Nuclear Translocation of RELB is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.
    Gastroenterology. 2018 Nov 13. pii: S0016-5085(18)35260.
    PubMed     Text format     Abstract available
    
    
19. VALOBRA T, Ceratti U, Gandino A
    Abdominal Septic Shock: An Eye-Popping Case.
    Gastroenterology. 2019;156:881-882.
    PubMed     Text format    
    
    
20. FRANSES JW, Zhu AX
    Has PD-1 MET its match in hepatocellular carcinoma?
    Gastroenterology. 2019 Mar 26. pii: S0016-5085(19)34585.
    PubMed     Text format    
    
    
21. NAULT JC, Nahon P
    Direct Antiviral Agents and the Risk of Recurrence of Hepatocellular Carcinoma: Moving on?
    Gastroenterology. 2019 Mar 26. pii: S0016-5085(19)34583.
    PubMed     Text format    
    
    

    
    Hepatology

22. KAO WY, Tan EC, Su CW
    Reply to comment: Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma.
    Hepatology. 2019 Mar 30. doi: 10.1002/hep.30632.
    PubMed     Text format     Abstract available
    
    
23. BROWN ZJ, Greten TF, Heinrich B
    Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.
    Hepatology. 2019 Mar 30. doi: 10.1002/hep.30633.
    PubMed     Text format     Abstract available
    
    
24. ZHOU SL, Yin D, Hu ZQ, Luo CB, et al
    A Positive Feedback Loop between Cancer Stem-Like Cells and Tumor- Associated Neutrophils Controls Hepatocellular Carcinoma Progression.
    Hepatology. 2019 Apr 1. doi: 10.1002/hep.30630.
    PubMed     Text format     Abstract available
    
    
25. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    PPIs in cirrhosis: more evidences for a careful prescription!
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30639.
    PubMed     Text format     Abstract available
    
    
26. MOON AM, Hayashi PH, Barritt AS 4th
    Proton pump inhibitors in cirrhosis: a marker of morbid conditions or cause of mortality.
    Hepatology. 2019 Apr 5. doi: 10.1002/hep.30642.
    PubMed     Text format     Abstract available
    
    
27. VUPPALANCHI R, Chalasani N
    HEP-18-0797.R2 - Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
    Hepatology. 2019 Apr 5. doi: 10.1002/hep.30640.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

28. SANCHEZ-MEJIAS A, Kwon J, Chew XH, Siemens A, et al
    A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer.
    Int J Cancer. 2019;144:311-321.
    PubMed     Text format     Abstract available
    
    

    
    J Comput Assist Tomogr

29. PIRIMOGLU B, Sade R, Islek A, Kantarci M, et al
    The Liver Fat Fraction and Abdominal Subcutaneous and Visceral Fat Volume Distribution in Normal-Weight, Overweight, and Obese Children Using a New Magnetic Resonance Imaging Technique.
    J Comput Assist Tomogr. 2019;43:194-199.
    PubMed     Text format     Abstract available
    
    
30. DIMMITT AM, Pelz JA, Albertson ME, Samson KK, et al
    Evaluation of Adaptive Statistical Iterative Reconstruction-V Reconstruction Algorithm vs Filtered Back Projection in the Detection of Hypodense Liver Lesions: Reader Performance and Preferences.
    J Comput Assist Tomogr. 2019;43:200-205.
    PubMed     Text format     Abstract available
    
    

    
    J Gastroenterol

31. MANO Y, Yoshio S, Shoji H, Tomonari S, et al
    Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
    J Gastroenterol. 2019 Apr 2. pii: 10.1007/s00535-019-01579.
    PubMed     Text format     Abstract available
    
    

    
    J Gastroenterol Hepatol

32. FOUAD TR, Abdelsameea E, Abdel-Razek W, Attia A, et al
    Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators.
    J Gastroenterol Hepatol. 2019 Mar 14. doi: 10.1111/jgh.14659.
    PubMed     Text format     Abstract available
    
    
33. HU KS, Tang B, Yuan J, Lu SX, et al
    A new sub-stage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2019 Apr 1. doi: 10.1111/jgh.14673.
    PubMed     Text format     Abstract available
    
    
34. LIU CH, Shih YL, Yang SS, Lin CL, et al
    Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East-Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
    J Gastroenterol Hepatol. 2019 Apr 1. doi: 10.1111/jgh.14672.
    PubMed     Text format     Abstract available
    
    

    
    J Hepatol

35. ARONSON SJ, Bakker RS, Shi X, Duijst S, et al
    Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.
    J Hepatol. 2019 Mar 29. pii: S0168-8278(19)30192.
    PubMed     Text format     Abstract available
    
    
36. JEONG KANG H, Oh JH, Chun SM, Kim D, et al
    Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    J Hepatol. 2019 Mar 28. pii: S0168-8278(19)30189.
    PubMed     Text format     Abstract available
    
    
37. MEYER T, Johnson P
    Trial endpoints for systemic therapy in patients with hepatocellular carcinoma.
    J Hepatol. 2019 Mar 11. pii: S0168-8278(19)30137.
    PubMed     Text format    
    
    

    
    Lancet Oncol

38. KRENS SD, Lassche G, Jansman FGA, Desar IME, et al
    Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
    Lancet Oncol. 2019;20:e200-e207.
    PubMed     Text format     Abstract available
    
    
39. ZHU AX, Finn RS, Galle PR, Llovet JM, et al
    Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein.
    Lancet Oncol. 2019;20:e191.
    PubMed     Text format    
    
    

    
    Oncogene

40. CUI Y, Wu X, Lin C, Zhang X, et al
    AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway.
    Oncogene. 2019 Apr 1. pii: 10.1038/s41388-019-0807.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

41. MOSTAFAEI F, Tai A, Omari E, Song Y, et al
    Variations of MRI-assessed peristaltic motions during radiation therapy.
    PLoS One. 2018;13:e0205917.
    PubMed     Text format     Abstract available
    
    
42. SUH JK, Lee J, Lee JH, Shin S, et al
    Risk factors for developing liver cancer in people with and without liver disease.
    PLoS One. 2018;13:e0206374.
    PubMed     Text format     Abstract available
    
    
43. JUN BG, Kim SG, Kim YD, Cheon GJ, et al
    Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for </=5cm hepatocellular carcinoma: Propensity score matching analysis.
    PLoS One. 2018;13:e0206381.
    PubMed     Text format     Abstract available
    
    
44. HANDGRAAF HJM, Sibinga Mulder BG, Shahbazi Feshtali S, Boogerd LSF, et al
    Staging laparoscopy with ultrasound and near-infrared fluorescence imaging to detect occult metastases of pancreatic and periampullary cancer.
    PLoS One. 2018;13:e0205960.
    PubMed     Text format     Abstract available
    
    
45. SILVA VIEIRA M, Arthurs CJ, Hussain T, Razavi R, et al
    Patient-specific modeling of right coronary circulation vulnerability post-liver transplant in Alagille's syndrome.
    PLoS One. 2018;13:e0205829.
    PubMed     Text format     Abstract available
    
    
46. SUWARTO S, Diahtantri RA, Hidayat MJ, Widjaya B, et al
    Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage.
    PLoS One. 2018;13:e0205965.
    PubMed     Text format     Abstract available
    
    

    
    Transplantation

47. EBADI M, Bhanji RA, Montano-Loza AJ
    Ethnic Disparities in the Prognosis of Cirrhosis.
    Transplantation. 2019 Apr 2. doi: 10.1097/TP.0000000000002734.
    PubMed     Text format    
    
    
48. ATIEMO K, Mazumder NR, Caicedo JC, Ganger D, et al
    The Hispanic Paradox in Patients with Liver Cirrhosis: Current Evidence from a Large Regional Retrospective Cohort Study.
    Transplantation. 2019 Apr 2. doi: 10.1097/TP.0000000000002733.
    PubMed     Text format     Abstract available
    
    
49. IONESCU MI, Tillakaratne S, Hodson J, Gunson B, et al
    Normothermic Machine Perfusion Enhances Intraoperative Hepatocellular Synthetic Capacity: A Propensity-Score Matched Analysis.
    Transplantation. 2019 Apr 1. doi: 10.1097/TP.0000000000002720.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: